1119280-66-8

Basic information

• Product Name: 2-CHLORO-5H-PYRROLO[3,2-D]PYRIMIDINE
• Synonyms: 2-CHLORO-5H-PYRROLO[3,2-D]PYRIMIDINE;2-Chloro-5H-pyrrolo[3,2-d...;2-chloro-5H-pyrrolo[3;5H-Pyrrolo[3,2-d]pyriMidine, 2-chloro-
• CAS NO: 1119280-66-8
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.56906
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 1119280-66-8.mol

Chemical Properties

• Melting Point: >230 °C
• Appearance: /
• Density: 1.531±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 12.25±0.40(Predicted)
• CAS DataBase Reference: 2-CHLORO-5H-PYRROLO[3,2-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5H-PYRROLO[3,2-D]PYRIMIDINE(1119280-66-8)
• EPA Substance Registry System: 2-CHLORO-5H-PYRROLO[3,2-D]PYRIMIDINE(1119280-66-8)

Safety Data

• Hazardous Substances Data: 1119280-66-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5H-pyrrolo[3,2-d]pyrimidine is used as a building block for the development of new drugs, leveraging its unique structural properties to create novel therapeutic agents. Its role in drug synthesis is crucial for the advancement of pharmaceutical research and the creation of innovative medications.
Used in Research Applications:
In the field of scientific research, 2-Chloro-5H-pyrrolo[3,2-d]pyrimidine serves as a valuable compound for studying the properties and interactions of pyrrolopyrimidines. It is used to explore the potential applications of these compounds in various areas, such as medicinal chemistry and drug discovery, contributing to the understanding of their biological activities and potential therapeutic uses.

Upstream product

• 63200-54-4 2,4-dichloro-5H-pyrrolo[3,2-d]pyrimidine 

Downstream Products

• 1152473-54-5 N-(4-morpholinophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine 
• 1152475-50-7 2-chloro-7-iodo-5H-pyrrolo[3,2-d]pyrimidine 
• 1429882-32-5 N-butyl-5-(4-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine 
• 1429882-33-6 7-bromo-N-butyl-5-(4-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine 
• 1429882-34-7 N-butyl-7-(4-(tert-butyldimethylsilyloxy)cyclohex-1-enyl)-5-(4-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-2-amine 
• 1429882-35-8 4-(2-(butylamino)-5-(4-fluorophenyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)cyclohex-3-enol? 
• 1429882-18-7 4-(2-(butylamino)-5-(4-fluorophenyl)-6,7-dihydro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)cyclohexanol 
• 1429882-36-9 7-bromo-2-chloro-5H-pyrrolo[3,2-d]pyrimidine 
• 1429882-37-0 7-bromo-2-chloro-5-trityl-5H-pyrrolo[3,2-d]pyrimidine 
• 1429882-38-1 4-((tert-butyldimethylsilyl)oxy)-1-(2-chloro-5-trityl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)cyclohexanol 
• 1429882-39-2 7-(4-((tert-butyldimethylsilyl)oxy)cyclohex-1-en-1-yl)-2-chloro-5-trityl-5H-pyrrolo[3,2-d]pyrimidine 
• 1429882-40-5 N-butyl-7-(4-((tert-butyldimethylsilyl)oxy)cyclohex-1-en-1-yl)-5-trityl-5H-pyrrolo[3,2-d]pyrimidin-2-amine 
• 1429882-43-8 4-(2-(butylamino)-5H-pyrrolo[3,2-d]pyrimidin-7-yl)cyclohexanone 

Relevant articles and documents

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist

The nuclear hormone receptor retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) is a promising target for the treatment of autoimmune diseases. A small molecule, inverse agonist of the receptor is anticipated to reduce production of IL-17, a key proinflammatory cytokine. Through a high-throughput screening approach, we identified a molecule displaying promising binding affinity for RORC2, inhibition of IL-17 production in Th17 cells, and selectivity against the related RORA and RORB receptor isoforms. Lead optimization to improve the potency and metabolic stability of this hit focused on two key design strategies, namely, iterative optimization driven by increasing lipophilic efficiency and structure-guided conformational restriction to achieve optimal ground state energetics and maximize receptor residence time. This approach successfully identified 3-cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide as a potent and selective RORC2 inverse agonist, demonstrating good metabolic stability, oral bioavailability, and the ability to reduce IL-17 levels and skin inflammation in a preclinical in vivo animal model upon oral administration.

RORC2 INHIBITORS AND METHODS OF USE THEREOF

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.

Method for selective dehalogenation in pyrimidine fused ring

The invention discloses a method for selective dehalogenation in pyrimidine fused ring. Through heating reaction between zinc powder and acetic acid solution, selective dehalogenation is conducted on pyrimidine ring to maintain original substituents on pyrimidine ring and fused ring. The method comprises few operation steps with high yield, and is applicable to mass production.

N-CONTAINING HETEROCYCLIC COMPOUNDS

The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.